[Pharmacology of several aromatic amino acid decarboxylase inhibitors].
D,L-beta-(3,4-dihydroxyphenyl)lactic acid (I), D,L-beta-(5-hydroxyindolyl-3)lactic acid (II), and L-alpha-methyl-DOPA (III) inhibited the aromatic amino acid decarboxylase (AAAD) competitively. In difference from the compound III, I and II were not AAAD substrates. Compound II selectively suppressed decarboxylation of L-5-hydroxytryptophane. Compounds I and III potentiated the excitation caused in mice by L-DOPA and failed to influence the excitation due to L-5-hudroxytryptophane (L-5-HTP). Compound II attenuated the excitation caused by L-DOPA and L-5-HTP. Pyridoxine hydrochloride and pyridoxalphosphate attenated the excitation caused by L-DOPA and L-5-HTP. Compounds I and III eliminated this action of vitamins B6.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000494:pharmacology*; D006916:5-Hydroxytryptophan / Q000494:pharmacology; D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D004347:Drug Interactions; D007211:Indoles / Q000494:pharmacology*; D007668:Kidney / Q000201:enzymology; D007773:Lactates / Q000494:pharmacology*; D007980:Levodopa / Q000494:pharmacology; D008750:Methyldopa / Q000494:pharmacology*; D010648:Phenylacetates / Q000494:pharmacology*; D011817:Rabbits
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D007211:Indoles; D007773:Lactates; D010648:Phenylacetates; D015102:3,4-Dihydroxyphenylacetic Acid; D007980:Levodopa; D008750:Methyldopa; D006916:5-Hydroxytryptophan
K farmakologii nekotorykh ingibitorov dekarboksilazy aromaticheskikh aminokislot.